Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

EURL PHARMACIE JEAN JAURES : revenue, balance sheet and financial ratios

EURL PHARMACIE JEAN JAURES is a French company founded 14 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in FLEURY-LES-AUBRAIS (45400), this company of category PME shows in 2025 a net income positive of 52 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - EURL PHARMACIE JEAN JAURES (SIREN 537854168)
Indicator 2025 2024 2023 2022 2021
Revenue N/C N/C N/C N/C N/C
Net income 52 434 € 69 715 € 88 404 € 89 593 € 99 793 €
EBITDA N/C N/C N/C N/C N/C
Net margin N/C N/C N/C N/C N/C

Revenue and income statement

In 2025, EURL PHARMACIE JEAN JAURES generates positive net income of 52 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2021-2025: 100 k€ -> 52 k€.

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

52 434 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 13%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 78%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

12.661%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

78.42%

Solvency indicators evolution
EURL PHARMACIE JEAN JAURES

Sector positioning

Debt ratio
12.66 2025
2023
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Excellent

In 2025, the debt ratio of EURL PHARMACIE JEAN JAURES (12.66) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.

Financial autonomy
78.42% 2025
2023
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Excellent +5 pts over 3 years

In 2025, the financial autonomy of EURL PHARMACIE JEAN JAURES (78.4%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.

Positioning of EURL PHARMACIE JEAN JAURES in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 277 transactions of similar company sales in 2025, the value of EURL PHARMACIE JEAN JAURES is estimated at 832 920 € (range 565 223€ - 1 306 966€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2025
277 transactions
565k€ 832k€ 1306k€
832 920 € Range: 565 223€ - 1 306 966€
NAF 5 année 2025

Valuation method used

Net Income Multiple
52 434 € × 15.9x = 832 920 €
Range: 565 224€ - 1 306 967€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare EURL PHARMACIE JEAN JAURES with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about EURL PHARMACIE JEAN JAURES

What is the revenue of EURL PHARMACIE JEAN JAURES ?

The revenue of EURL PHARMACIE JEAN JAURES is not publicly disclosed (confidential accounts filed with INPI).

Is EURL PHARMACIE JEAN JAURES profitable?

Yes, EURL PHARMACIE JEAN JAURES generated a net profit of 52 k€ in 2025.

Where is the headquarters of EURL PHARMACIE JEAN JAURES ?

The headquarters of EURL PHARMACIE JEAN JAURES is located in FLEURY-LES-AUBRAIS (45400), in the department Loiret.

Where to find the tax return of EURL PHARMACIE JEAN JAURES ?

The tax return of EURL PHARMACIE JEAN JAURES is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does EURL PHARMACIE JEAN JAURES operate?

EURL PHARMACIE JEAN JAURES operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.